Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil (Q40352545)

19 September 2017

title

Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil (English)

1 reference

19 September 2017

Corbin J

1

1 reference

19 September 2017

Francis S

series ordinal

2

1 reference

19 September 2017

Zoraghi R

series ordinal

3

1 reference

19 September 2017

publication date

1 May 2006

1 reference

International Journal of Impotence Research

19 September 2017

published in

1 reference

19 September 2017

volume

18

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

251-257

1 reference

Cyclic GMP phosphodiesterase-5: target of sildenafil

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Phosphodiesterase 5 inhibitors: current status and potential applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Pharmacological management of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Erectile dysfunction: evaluation and new treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Single step isolation of sildenafil from commercially available Viagra™ tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Functional group contributions to drug-receptor interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

7 January 2021

Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

7 January 2021

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

7 January 2021

Site-directed mutagenesis as a probe of enzyme structure and catalysis: tyrosyl-tRNA synthetase cysteine-35 to glycine-35 mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

7 January 2021

Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901411

7 January 2021

Identifiers

DOI

10.1038/SJ.IJIR.3901411

1 reference

Dimensions Publication ID

19 September 2017

1052757664

0 references

1 reference